Journal article
Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials
American journal of health-system pharmacy, Vol.72(11), pp.958-965
06/01/2015
DOI: 10.2146/ajhp140591
PMCID: PMC4510955
PMID: 25987691
Abstract
Purpose. Potential cytochrome P-450 (CYP) drug-drug interactions in adults with metastatic solid tumors and their effect on eligibility for Phase I clinical trials were characterized.
Methods. This study included adult patients with metastatic solid tumors seen by a medical oncologist from January 2008 through July 2011. The medications used by these patients were identified. Each medication's potential for interacting with CYP isozymes was also characterized. Medication changes required to meet Phase trial eligibility criteria were also reviewed.
Results. Data from 1773 patients were analyzed: 1489 were not enrolled in a Phase I trial and 284 were enrolled in a Phase I trial. Polypharmacy was significantly more prevalent in the group enrolled in a Phase I trial compared with those not enrolled (95% versus 80%, p < 0.001). The majority of patients not enrolled in a Phase I trial were taking at least one CYP isozyme inhibitor (87%) and at least one CYP isozyme inducer (45%). In a separate analysis, four Phase I trials were evaluated. Of 295 screened patients, 3.2% could not enroll due to concurrent medications. Charts from 74 enrolled patients revealed 655 concurrent medications-93 medications required further review for eligibility involving 51(69%) of patients. Of the 93 medications, 38(41%) were stopped and 41 (44%) were changed for the study.
Conclusion. Polypharmacy and the use of medications that interact with CYP isoyzmes were common in adult patients with metastatic solid tumors. Patients enrolling in Phase I studies often require medication changes to meet eligibility requirements.
Details
- Title: Subtitle
- Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials
- Creators
- Kari B. Wisinski - University of Wisconsin Carbone Cancer CenterColby A. Cantu - Faculty of Public HealthJens Eickhoff - Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI 53706 USAKurt Osterby - UW Health University HospitalAmye J. Tevaarwerk - University of Wisconsin Carbone Cancer CenterJennifer Heideman - University of Wisconsin Carbone Cancer CenterGlenn Liu - University of Wisconsin Carbone Cancer CenterGeorge Wilding - University of Wisconsin Carbone Cancer CenterSusan Johnston - University of Wisconsin Carbone Cancer CenterJill M. Kolesar - University of Wisconsin Carbone Cancer Center
- Resource Type
- Journal article
- Publication Details
- American journal of health-system pharmacy, Vol.72(11), pp.958-965
- DOI
- 10.2146/ajhp140591
- PMID
- 25987691
- PMCID
- PMC4510955
- NLM abbreviation
- Am J Health Syst Pharm
- ISSN
- 1079-2082
- eISSN
- 1535-2900
- Publisher
- Amer Soc Health-System Pharmacists
- Number of pages
- 8
- Grant note
- UL1TR000042 / NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Advancing Translational Sciences (NCATS) P30 CA014520; U01 CA062491-19S1 / National Cancer Institute Cancer Center Support Grant; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) P30CA014520 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) UL1TR00042 / National Institutes of Health National Center for Advancing Translational Sciences KL2RR025012 / NATIONAL CENTER FOR RESEARCH RESOURCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Center for Research Resources (NCRR) Shapiro Summer Research Program, Conquer Cancer Foundation of the American Society of Clinical Oncology Medical Student Rotation for Underrepresented Populations - Doris Duke Charitable Foundation
- Language
- English
- Date published
- 06/01/2015
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696552302771
Metrics
2 Record Views